Received: 11 January 2022; Published on-line: 15 March 2022
Efficacy of the modified staged method of surgical treatment for proliferative diabetic retinopathy
Vira S Ponomarchuk, A. R. Korol, M. M. Umanets
SI "The Filatov Institute of Eye Diseases and Tissue Therapy of the NAMS of Ukraine"; Odesa (Ukraine)
TO CITE THIS ARTICLE: Ponomarchuk Vira S, Korol A. R., Umanets M. M. Efficacy of the modified staged method of surgical treatment for proliferative diabetic retinopathy. J.ophthalmol.(Ukraine).2022;1:30-6. http://doi.org/10.31288/oftalmolzh20223036
Background. Anti-vascular endothelial growth factor (VEGF) agents have been successfully used to reduce the incidence of perioperative and postoperative complications in patients with proliferative diabetic retinopathy (PDR).
Purpose: To evaluate the efficacy of a modified staged method of surgical treatment for PDR which involves intravitreal aflibercept (IVA) injection 1-mg prior to vitrectomy.
Material and Methods: This study involved 75 patients (75 eyes) with PDR. Group 1 (the control group) received vitrectomy only; Group 2, IVA 1.0 mg prior to vitrectomy; and Group 3, IVA 2.0 mg prior to vitrectomy.
Results: Mean visual acuity at 2 months and 6 months was significantly better in eyes treated with aflibercept than in those not treated with aflibercept (p1-2 = 0.0001; p1-3 = 0.0001). In the early postoperative period, transient vitreous hemorrhage was observed significantly more frequently in the control group than in group 2 (p1-2 = 0.0003) or group 3 (p1-3 = 0.0004). The incidence of transient vitreous hemorrhage within 2 months after vitrectomy was also significantly higher in the control group than in group 2 (p1-2=0.09) or group 3 (p1-2=0.017). By 6 months after surgery, rubeosis developed in 5 eyes (16.1%) of the control group, and in no eye of the 44 eyes that received intravitreal aflibercept (р= 0.02).
Conclusion: Our modified staged method of surgical treatment for PDR enabled an improvement in visual acuity at 2 months and 6 months after surgery; a reduction in the incidence of transient vitreous hemorrhage in the early postoperative period; and reduction in the risk of the development of iris rubeosis in the late period after surgery.
Keywords: proliferative diabetic retinopathy, intravitreal aflibercept, vitrectomy
1.Zheng Y, He M, Congdon N. The worldwide epidemic of diabetic retinopathy. Indian J Ophthalmol. 2012; 60(5): 428-31.
2.Schachat AP, Oyakawa RT, Michels RG, Rice TA. Complications of vitreous surgery for diabetic retinopathy. II. Postoperative complications. Ophthalmology. 1983; 90(5): 522-30.
3.Novak MA, Rice TA, Michels RG. Vitreous hemorrhage after vitrectomy for diabetic retinopathy. Ophthalmology. 1984 Dec;91(12):1485-9.
4.Blankenship GW. Management of vitreous cavity hemorrhage following pars plana vitrectomy for diabetic retinopathy. Ophthalmology. 1986 Jan;93(1):39-44.
5.Tolentino FI, Cajita VN, Gancayco T, Skates S. Vitreous hemorrhage after closed vitrectomy for proliferative diabetic retinopathy. Ophthalmology. 1989 Oct;96(10):1495-500.
6.Neely KA, Scroggs MW, McCuen BW II. Peripheral retinal cryotherapy for postvitrectomy diabetic vitreous hemorrhage in phakic eyes. Am J Ophthalmol. 1998 Jul;126(1):82-90.
7.Yeh PT, Yang CM, Yang CH. Cryotherapy of the anterior retina and sclerotomy sites in diabetic vitrectomy to prevent recurrent vitreous hemorrhage: an ultrasound biomicroscopy study. Ophthalmology. 2005 Dec;112(12):2095-102.
8.Yang CM, Yeh PT, Yang CH. Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology. 2007 Apr;114(4):710-5.
9.Wang DY, Zhao XY, Zhang WF. Perioperative anti-vascular endothelial growth factor agents treatment in patients undergoing vitrectomy for complicated proliferative diabetic retinopathy: a network meta-analysis. Sci Rep. 2020 Nov 3;10(1):18880.
10.Pasyechnikova NV, Naumenko VO, Korol AR, Zadorozhnyy OS, Kustryn TB, Henrich PB. Intravitreal ranibizumab for the treatment of choroidal neovascularizations associated with pathologic myopia: a prospective study. Ophthalmologica. 2015;233(1):2-7.
11.Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. Jul-Aug 2006;26(6):699-700.
12.Yeoh J, Williams C, Allen P. Avastin as an adjunct to vitrectomy in the management of severe proliferative diabetic retinopathy: a prospective case series. Clin Exp Ophthalmol. 2008 Jul;36(5):449-54.
13.Rizzo S, Genovesi-Ebert F, Di Bartolo E. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefes Arch Clin Exp Ophthalmol. 2008 Jun;246(6):837-42.
14.El-Batarny AM. Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy. Clin Ophthalmol. 2008 Dec;2(4):709-16.
15.Ahmadieh H, Shoeibi N, Entezari M. Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology. 2009 Oct;116(10):1943-8.
16.Yeh PT, Yang CM, Lin YC. Bevacizumab pretreatment in vitrectomy with silicone oil for severe diabetic retinopathy. Retina. 2009 Jun;29(6):768-74.
17.Ponomarchuk Vira S, Umanets MM, Velychko LM. [Vitreous VEGF levels and features of vitrectomy after intravitreal injection of various doses of aflibercept in patients with proliferative diabetic retinopathy]. In: [Proceedings of the National Conference on Current Issues of Ophthalmology]. September 22-23, 2021. Mykolaiv, Ukraine. Ukrainian.
18.Ponomarchuk Vira S, Velychko LM, Umanets MM. Vitreous VEGF levels among patients with proliferative diabetic retinopathy depending on the general clinical status and ocular status. J Ophthalmol (Ukraine). 2021;4: 19-25.
19.Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol. 2002 Dec;29(6 Suppl 16):10-4.
20.Korol A, Kustryn T, Zadorozhnyy O. Comparison of Efficacy of Intravitreal Ranibizumab and Aflibercept in Eyes with Myopic Choroidal Neovascularization: 24-Month Follow-Up. J Ocul Pharmacol Ther. 2020 Mar;36(2):122-125.
21.Gupta A, Bansal R, Gupta V. Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab. Int Ophthalmol. 2012 Apr;32(2):135-44.
22.Hu L, Chen Q, Du Z. Evaluation of vitrectomy combined preoperative intravitreal ranibizumab and postoperative intravitreal triamcinolone acetonide for proliferative diabetic retinopathy. Int Ophthalmol. 2021 May;41(5):1635-1642.
23.Lo WR, Kim SJ, Aaberg TM Sr. Visual outcomes and incidence of recurrent vitreous hemorrhage after vitrectomy in diabetic eyes pretreated with bevacizumab (avastin). Retina. Jul-Aug 2009;29(7):926-31.
24.Velazquez JC, Aleman I, Rush SW. Bevacizumab before Diabetic Vitrectomy: A Clinical Trial Assessing 3 Dosing Amounts. Ophthalmol Retina. 2018 Oct;2(10):1010-1020.
25.Zhao LQ, Zhu H, Zhao PQ. A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol. 2011 Sep;95(9):1216-22.
26.Ruban AM. [Risk factors for neovascular glaucoma after miniinvasive vitrectomy for proliferative diabetic retinopathy]. Medychna informatika ta inzheneriia. 2014;3:51-6. Ukrainian.
Acknowledgement: The authors thank O.I. Dragomiretska for her assistance in statistic analysis.
Author Contributions: Vira S. Ponomarchuk: conducting intravitreal injections, data collection and analysis, writing the text; A.R. Korol: idea to use 1 mg aflibercept, editing the text; M.M.Umanets: concept and design of the study, surgical interventions, and editing.
Disclosures: The authors declare no conflict of interest.
Source of support: There are no external sources of funding.